Risk Factors of Sakurada et al for Interstitial Lung Disease (ILD) Associated with Chemotherapy for Lung Cancer

Description

Sakurada et al identified risk factors for interstitial lung disease (ILD) developing in a patient being treated for lung cancer. These can help to identify a patient who may require more careful treatment planning to avoid this complication. The authors are from the University of Tokushima and Kyushu University Hospital in Japan.

Patient selection: lung cancer

Outcome: interstitial lung disease (ILD)

Risk factors (and prognostic factors) for interstitial lung disease:

(1) pre-existing interstitial lung disease

(2) therapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) such as erlotinib (see above)

(3) >= 2 previous chemotherapy regimens

Symptoms associated with chemotherapy-induced ILD:

(1) unexplained fever

(2) onset or worsening of cough

(3) onset or worsening of dyspnea

A chest X-ray may show ground-glass opacities, consolidation and/or reticular shadow even in the absence of symptoms.

To read more or access our algorithms and calculators, please log in or register.

Description

Specialty

ICD-10